The relationship between systemic therapies and low skeletal muscle mass in patients with intermediate and advanced hepatocellular carcinoma

The relationship between systemic therapies and low skeletal muscle mass in patients with intermediate and advanced hepatocellular carcinoma

BackgroundLow skeletal muscle mass (LSMM) has been associated with poor prognosis in hepatocellular carcinoma (HCC) patients receiving systemic therapy. However, its impact across different treatment regimens remains unclear.MethodsA retrospective study analyzed 714 patients with intermediate and ad...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jingjing Chen, Xueying Huang, Qiaoxin Wei, Songtao Liu, Wenyan Song, Mei Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Immunology
Subjects:	hepatocellular carcinoma systemic therapy immunotherapy targeted immunotherapy combination treatment targeted therapy low skeletal muscle mass
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1557839/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Therapeutic advances in hepatocellular carcinoma: an update from the 2024 ASCO annual meeting
by: Hongyuan Yang, et al.
Published: (2024-10-01)

Efficacy and safety of radiotherapy combined with immunotherapy and targeted therapy versus immunotherapy plus targeted therapy alone in unresectable hepatocellular carcinoma: a retrospective study
by: Yanling Yuan, et al.
Published: (2025-08-01)

Neoadjuvant therapy for hepatocellular carcinoma—priming precision innovations to transform HCC treatment
by: Kristin E. Goodsell, et al.
Published: (2025-03-01)

Targeted nanoparticle delivery unleashes synergistic photothermal and immunotherapeutic effects against hepatocellular carcinoma
by: Amal Babu, et al.
Published: (2024-12-01)

Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia
by: Zhiyuan Zhong, et al.
Published: (2025-07-01)

Sequential surgery following Yttrium-90 resin microspheres combined with targeted therapy and immunotherapy for primary hepatocellular carcinoma: a case report
by: Fang-Yuan Hu, et al.
Published: (2025-07-01)

Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy
by: Yun Feng, et al.
Published: (2025-04-01)

Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience
by: Zizhuo Wang, et al.
Published: (2025-01-01)

Prognostic nutritional index predicts survival in intermediate and advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with PD-(L)1 inhibitors and molecular targeted therapies
by: Hao-Huan Tang, et al.
Published: (2025-04-01)

Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)
by: Zhi‐Cheng Jin, et al.
Published: (2024-12-01)

Prospect of extracellular vesicles in tumor immunotherapy
by: Wenbo Xia, et al.
Published: (2025-02-01)

Prognostic comparison between pulmonary metastasectomy and combination immunotherapy with targeted molecular therapies for advanced hepatocellular carcinoma with pulmonary metastasis: A propensity score matching analysis
by: Juxian Sun, et al.
Published: (2025-03-01)

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives
by: Dong Luo, et al.
Published: (2025-02-01)

Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma
by: Jie YANG, et al.
Published: (2025-05-01)

The role of prognostic nutrition index in the prognosis of patients with advanced hepatocellular carcinoma who received first-line therapy
by: Jianwei Liu, et al.
Published: (2025-08-01)

Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors
by: Chen W, et al.
Published: (2025-02-01)

Recent advances and challenges of cellular immunotherapies in lung cancer treatment
by: Chengfei Yang, et al.
Published: (2025-07-01)

The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM
by: Jiahao Li, et al.
Published: (2025-04-01)

Wnt/β-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy
by: Xiuzhu Wu, et al.
Published: (2025-06-01)

Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches
by: Xiaofang Li, et al.
Published: (2025-02-01)

Combination Therapy of Transarterial Chemoembolization, Lenvatinib, and PD-1 Inhibitors Achieves Significant Tumor Response in Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report
by: Fu Y, et al.
Published: (2025-04-01)

Comparative efficacy of glioma treatment strategies: an umbrella review of meta-analyses
by: Erming Yang, et al.
Published: (2025-12-01)

Comment on ‘Factors Associated With Skeletal Muscle Mass in Middle‐Aged Men Living With HIV’ by Xu et al.
by: Wanfeng Qian, et al.
Published: (2024-12-01)

Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study
by: Chen X, et al.
Published: (2025-03-01)

Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: findings from a single-center retrospective study
by: Hongliang Liu, et al.
Published: (2025-01-01)

Unraveling the triad of immunotherapy, tumor microenvironment, and skeletal muscle biomechanics in oncology
by: Shuang Ma, et al.
Published: (2025-04-01)

Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy
by: Ulas Kumbasar, et al.
Published: (2025-06-01)

Telerehabilitation is Effective to Recover Functionality and Increase Skeletal Muscle Mass Index in COVID-19 Survivors
by: Jorge Cancino-López, et al.
Published: (2021-12-01)

Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma
by: Marìa Margarita Anders, et al.
Published: (2025-07-01)

Current status of cytokine-induced killer cells and combination regimens in breast cancer
by: Yuancong Jiang, et al.
Published: (2025-02-01)

MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPY
by: A. S. Makarova
Published: (2017-12-01)

Impact of chest computed tomography-determined low skeletal muscle mass on the survival of patients with acute heart failure
by: Yan Huang, et al.
Published: (2025-08-01)

Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment
by: G. P. Guens, et al.
Published: (2021-11-01)

Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
by: Shenao Fu, et al.
Published: (2025-07-01)

CyTOF reveals platelet subtype changes predicting the efficacy of combined immunotherapy and targeted therapy in liver cancer
by: Wenjing Wang, et al.
Published: (2025-05-01)

Targeting cuproptosis with nano material: new way to enhancing the efficacy of immunotherapy in colorectal cancer
by: Xiangdong Liu, et al.
Published: (2024-12-01)

Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment
by: Shujie Liu, et al.
Published: (2025-05-01)

Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta‐analysis
by: Shugo Yajima, et al.
Published: (2025-05-01)

Molecular subtyping and precision therapy for esophageal cancer
by: Guangkun Pei, et al.
Published: (2025-05-01)

Exploration of Traditional Chinese Medicine Comprehensive Treatment of Triple Negative Breast Cancer Based on Molecular Pathological Mechanism
by: Zhu M, et al.
Published: (2025-04-01)